Catalyst ligands

4479-74-7,4479-74-7, 2,2-Bipyridine-6,6-dicarboxylic Acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of 2,2?-bipyridine-6,6?-dicarboxylic acid (244 mg,1.0 mmol), Ru(DMSO)4Cl2 (484 mg, 1.0 mmol), and Et3N (0.8ml) in methanol (10 ml) was degassed with N2 and refluxed for 4 h. The solution changed from bright yellow to dark before the appearance of a brown precipitate. After cooling to room temperature, the precipitate was filtered and washed with methanol (10 ml ¡Á 3) and ether (10 ml ¡Á 3) to get a reddish-brown powder. The powder was mixed with an excess of 4,4?-bipyridine in methanol (20 ml) and heated to reflux for 2 h. The solvent was removed and the resulted residue was re-dissolved in dichloromethane, washed with water to remove triethylamine hydrochloride, and dried over MgSO4 under N2. After purification by column chromatography on silica gel with dichloromethane-methanol (20:1 to 1:1, V:V) as eluent, complex1 was obtained as a dark red solid. Yield: 229 mg (35%).

The synthetic route of 4479-74-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Jiang, Yi; Li, Fei; Huang, Fang; Zhang, Biaobiao; Sun, Licheng; Cuihua Xuebao/Chinese Journal of Catalysis; vol. 34; 8; (2013); p. 1489 – 1495;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103946-54-9, 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 10; Synthesis of dye; 57 mg of a product was obtained in the same manner as the “synthesis of dye” in Example 5 except that 34.28 mg of 4-carboxy-4′-methyl-2,2′-bipyridine (synthesized in the “synthesis of ligand” in Example 5) was used in place of 39. 08 mg of 4,4′ -dicarboxy-2,2′ -bipyridine used in the “synthesis of dye” in Example 5. It was found that the product was one represented by the above formula (22) by 1H-NMR analysis. 1H-NMR (DMSO-d6, 298K, 270MHz, delta(ppm)) ; delta = 9.41 (m, 1H), 9.06-8.70 (m, 5H), 8.27 (m, 1H), 7.82-7.12 (m, 5H), 2.68 (s, 3H), 2.42 (s, 3H)

103946-54-9, As the paragraph descriping shows that 103946-54-9 is playing an increasingly important role.

Reference£º
Patent; JSR Corporation; EP1767588; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.56-54-2,(S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

56-54-2, 4-Hydroxyphenylacetic acid (40 mg,0.263 mmol) and quinidine (85.3 mg, 0.263 mmol) were dissolved in ethanol, and after 2 weeks crystals were obtained. Similar crystals were obtained using methanol, isopropanol and tetrahydrofuranas solvents.

As the paragraph descriping shows that 56-54-2 is playing an increasingly important role.

Reference£º
Article; Amombo Noa, Francoise M.; Jacobs, Ayesha; Journal of Molecular Structure; vol. 1114; (2016); p. 30 – 37;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

56-54-2, (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

56-54-2, General procedure: 4.24.12 N-(3,5-Ditrifluoromethyl)benzyl-6′-hydroxyquinidi-nium bromide (4c) Ethanethiol (2.30 mL, 30.8 mmol) was added under argon atmosphere to a stirred suspension of sodium hydride (370.0 mg, 15.4 mmol) in dry DMF (15 mL). Quinidine (500 mg, 1.5 mmol) in dry DMF (7.5 mL) was added dropwise and the reaction mixture was stirred at 110 C for 13 h. The solvent and excess ethanethiol were removed under reduced pressure. Then the 3,5-ditrifluoromethylbenzyl bromide (675.4 mg, 2.2 mmol) was added in THF (9 mL). The reaction mixture was refluxed and monitored by TLC analysis. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (MeOH/EtOAc = 1/20, V/V). Yield 52%; white solid; mp 258 C (decomp.); [alpha]D28 +182.3 (c 0.16, CH3OH); IR (KBr): 3369, 3234, 1622, 1531, 1469, 1217, 1181, 1135, 1003, 927, 905, 864, 842, 736, 709, 683 cm-1; 1H NMR (400 MHz, DMSO-d6): delta = 10.06 (s, 1H), 8.75 (d, J = 4.4 Hz, 1H), 8.63 (s, 2H), 8.37 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.70 (d, J = 4.4 Hz, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.38 (dd, J = 9.0, 2.2 Hz, 1H), 6.68 (d, J = 3.6 Hz, 1H), 6.32 (s, 1H), 6.02 (ddd, J = 17.4, 10.5, 6.9 Hz, 1H), 5.38 (d, J = 12.4 Hz, 1H), 5.26-5.19 (m, 3H), 4.32 (t, J = 9.6 Hz, 1H), 4.13 (t, J = 9.6 Hz, 1H), 3.92 (t, J = 9.6 Hz, 1H), 3.49 (t, J = 11.2 Hz, 1H), 3.12-3.05 (m, 1H), 2.65-2.59 (m, 1H), 2.33 (t, J = 11.6 Hz, 1H), 1.89 (s, 1H), 1.83-1.78 (m, 2H), 1.17-1.09 (m, 1H); 13C NMR (100 MHz, DMSO-d6): delta = 156.5, 147.2, 143.4, 143.1, 137.7, 135.2, 131.9, 131.7, 131.2 (q, J = 33.0 Hz), 126.1, 124.6 (q, J = 3.2 Hz), 123.7 (q, J = 271.8 Hz), 122.2, 120.4, 117.6, 105.1, 68.2, 65.3, 60.9, 56.3, 54.7, 37.3, 26.9, 23.6, 21.0; HRMS calcd for [C28H27F6N2O2]+: 537.1971, found 537.1959.

56-54-2 (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol 637552, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Wu, Shaoxiang; Guo, Jiyi; Sohail, Muhammad; Cao, Chengyao; Chen, Fu-Xue; Journal of Fluorine Chemistry; vol. 148; (2013); p. 19 – 29;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: Complexes were synthesized using the following general procedure: to an ethanolic (or methanolic) solution of glycine (1mmol) and NaOH (1mmol) salicylaldehyde (1mmol) was added. The resulting yellow solution was stirred for 30min at room temperature and a solution of Zn(CH3COO)2.2H2O (1mmol in 5mL of water) was added dropwise. The pH was adjusted to 7 with 1M NaOH and the mixture was stirred at room temperature for 1h. The polypyridyl (1mmol) in ethanol (10mL) was then added and the resulting solution stirred at room temperature for 1h, subsequently concentrated and left overnight at 4C. The precipitate obtained was filtered, washed with cold ethanol and diethyl ether and dried in vacuum., 1662-01-7

As the paragraph descriping shows that 1662-01-7 is playing an increasingly important role.

Reference£º
Article; Matos, Cristina P.; Addis, Yemataw; Nunes, Patrique; Barroso, Sonia; Alho, Irina; Martins, Marta; Matos, Antonio P.A.; Marques, Fernanda; Cavaco, Isabel; Costa Pessoa, Joao; Correia, Isabel; Journal of Inorganic Biochemistry; vol. 198; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

56-54-2, (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

56-54-2, General procedure: An oven-dried culture tube containing the tetrayne precursor in organic solvent (initial concentration of 0.02-0.03 M) and the indicated number of equivalents of trapping component(s) was closed with a Teflon-lined cap and the solution was heated at 85-90 C for 16 h. The half-life for conversion of each of the polyynes used here to the corresponding benzyne was approx. 3-4 h. The product(s) was separated and purified by chromatography on silica gel. Full experimental details and characterization data for all new compounds (polyyne HDDA substrates andproducts) and a description of the computational methods and results are providedin the Supplementary Information.

As the paragraph descriping shows that 56-54-2 is playing an increasingly important role.

Reference£º
Article; Ross, Sean P.; Hoye, Thomas R.; Nature Chemistry; vol. 9; 6; (2017); p. 523 – 530;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17217-57-1,4,4′-Dimethoxy-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

General procedure: [Rh(bpy)2(4,4′-dmobpy)](PF6)3 was prepared as above but using cis-[Rh(bpy)2(OTf)2](OTf) (102 mg, 0.118 mmol) and4,4′-dimethoxy-2,2′-bipyridine (29.3 mg, 0.135 mmol) in 10 mL ethanol and refluxing for 30 min. Yield of analytically pure,off-white product (110 mg, 0.100 mmol), 84percent. Anal. Calcd forC32H28N6RhO4P3F18: C, 34.99; H, 2.57; N, 7.65. Found: C, 35.00; H,2.58; N, 7.55. 1H NMR (d6-DMSO, 400 MHz): d (ppm) aromaticprotons [9.04 (d, J = 8.23 Hz, 4H), 8.67 (d, J = 2.49 Hz, 2H), 8.57 (q,J = 7.95 Hz, 4H), 7.91 (d, J = 5.74 Hz, 2H), 7.84 (t, J = 8.18 Hz, 2H),7.79 (q, J = 5.82 Hz, 4H), 7.57 (d, J = 6.83 Hz, 2H), 7.30 (dd,J = 6.34 Hz, 2H)], 4.08 (s, 6H, OCH3). 13C NMR (d6-DMSO,100 MHz): d (ppm) aromatic carbons [169.8, 155.6, 154.6, 154.5,151.2, 151.0, 150.7, 143.0, 130.4, 126.7, 120.6, 115.6, 113.7], 57.7(OCH3).

17217-57-1, 17217-57-1 4,4′-Dimethoxy-2,2′-bipyridine 2733927, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Amarante, Daniel; Cherian, Cheryl; Megehee, Elise G.; Inorganica Chimica Acta; vol. 461; (2017); p. 239 – 247;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: A solution of x,y-bis(bromomethyl)-1,1′-biphenyl (x,y = 3,3? or 4,4?) (3,3′-bis(bromomethyl)-1,1′-biphenyl/ 4,4′-bis(bromomethyl)-1,1′-biphenyl)S2 (68.0 mg, 200 mumol) was added to a solution of tri-tert-butyl1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (25.0 mg, 500 mumol), K2CO3 (6.90 mg, 500 mumol)in CH3CN (1.50 mL) under N2 and stirred for 12 hr at room temperature. The reaction mixture wasconcentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with waterand brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protectedamine intermediates. A solution of the intermediates was added to bis(pyridin-2-ylmethyl)amine (15.3 mg,77.0 mumol), KI (2.50 mg, 15.0 mumol) and K2CO3 (2.10 mg, 15.0 mumol) in CH3CN (5.00 mL) under N2 andstirred at 80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted withEtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuoto obtain the corresponding tri-N-Boc-protected amine intermediates. The intermediates were thendissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixturewas concentrated under reduced pressure and purified by preparative HPLC to obtain the desiredcompounds 4-5.

170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

0.440 g (2.07 mmol) of (S,S)-DPEN (MW: 212.3) was introduced into a 100-mL three-necked flask and subjected to argon-gas replacement. 20 mL of dehydrated methylene chloride and 0.303 mL (2.17 mmol) of triethylamine were added and cooled to 0 C. To this solution, a solution consisting of 0.520 g (2.07 mmol) of 3′,5′-dimethoxyphenyl methanesulfonyl chloride (MW: 250.70) and 5 mL of dehydrated methylene chloride was slowly added dropwise, and stirred at 0 C. for 3 hr. This solution was washed twice with water, the solvent in the organic layer was distilled away, and dried under reduced pressure to give a crude product. The crude product was purified by silica-gel column chromatography (silica gel 60N, n-hexane:AcOEt=1:1, then AcOEt 100%) to give 0.51 g of (S,S)-(3′,5′-dimethoxyphenyl)methane-SO2DPEN (58% yield). 1H NMR (400 MHz, CDCl3, rt, delta/ppm): 3.59 (d, J=13.7 Hz, 1H, SO2C2C6H3), 3.64 (d, J=13.7 Hz, 1H, SO2C2C6H3), 3.71 (s, 6H, (OC3)2), 4.23 (d, J=6.4 Hz, 1H, CNH2), 4.59 (d, J=6.4 Hz, 1H, CNHSO2), 6.29 (d, J=2.3 Hz, 2H, C62H (OCH3)2), 6.36 (d, J=2.3 Hz, 1H, C6H2(OCH3)2), 7.18-7.40 (m, 10H, aromatic proton)., 29841-69-8

As the paragraph descriping shows that 29841-69-8 is playing an increasingly important role.

Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; US2010/261924; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13093-04-4,N1,N6-Dimethylhexane-1,6-diamine,as a common compound, the synthetic route is as follows.

EXAMPLE III N,N’-Dimethyl-N,N’-hexamethylene-bis[3-(N,N-dibenzyl aminoxy)propionamide] A solution of 6.4 g of 3-(N,N-dibenzylaminoxy) propanoic acid in 25 ml of methylene chloride is admixed with 1.8 ml of oxalyl chloride at 0-5 C. After 2 hours, a solution of 8.61 g N,N’-dimethyl hexamethylenediamine in 25 ml of methylene chloride is added at 0 C. and the reaction mixture is stirred at room temperature for 12 hours. The insoluble salt residue is removed by filtration and methylene chloride is removed under reduced pressure. Purification by liquid chromatography affords the title compound as a thick oil.

13093-04-4, As the paragraph descriping shows that 13093-04-4 is playing an increasingly important role.

Reference£º
Patent; Ciba-Geigy Corporation; US4760179; (1988); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI